Abstract
The effects of soy protein and isoflavones on blood cholesterol in humans has been variable. Maximal low- density lipoprotein cholesterol lowering appears to be modest and consistently ranges from 5% to 7%. Preliminary evidence suggests a potentially beneficial effect of the isoflavone fraction of soybeans on arterial compliance. The isoflavone fraction has been demonstrated to decrease the in vitro susceptibility of low-density lipoprotein to oxidation; the significance of this finding in vivo is unknown. It is difficult to definitively say at this time whether increased consumption of soy based products will result in a decreased risk of CHD beyond their ability to displace foods high in saturated fat and cholesterol from the diet.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
